Kei Yasuda

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo
    Petar Lenert
    Department of Internal Medicine and Pathology, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, USA
    Arthritis Res Ther 11:R79. 2009
  2. ncbi Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes
    Kei Yasuda
    Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 183:3109-17. 2009
  3. ncbi IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus
    Christophe Richez
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 184:796-806. 2010
  4. ncbi TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming
    Christophe Richez
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 182:820-8. 2009
  5. ncbi Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production
    Kei Yasuda
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 178:6876-85. 2007
  6. ncbi The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin
    Tamar Aprahamian
    Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 182:340-6. 2009
  7. ncbi Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop
    Nathaniel M Green
    Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 183:1569-76. 2009
  8. ncbi Role of immunostimulatory DNA and TLR9 in gene therapy
    Kei Yasuda
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Crit Rev Ther Drug Carrier Syst 23:89-110. 2006

Collaborators

Detail Information

Publications8

  1. ncbi DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo
    Petar Lenert
    Department of Internal Medicine and Pathology, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, USA
    Arthritis Res Ther 11:R79. 2009
    ..Thus, strategies to preferentially block innate activation through TLRs in autoimmune B cells may be preferred over non-selective B-cell depletion...
  2. ncbi Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes
    Kei Yasuda
    Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 183:3109-17. 2009
    ....
  3. ncbi IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus
    Christophe Richez
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 184:796-806. 2010
    ..Overall, we demonstrate that IRF5 plays an essential role in lupus pathogenesis in murine models and that this is mediated through pathways beyond that of type I IFN production...
  4. ncbi TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFN-beta priming
    Christophe Richez
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 182:820-8. 2009
    ..This data demonstrates a novel pathway for IFN-alpha production by cDCs and provides one possible explanation for how bacterial infection might precipitate disease flares in SLE...
  5. ncbi Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production
    Kei Yasuda
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 178:6876-85. 2007
    ..This system may also prove useful for the study of receptors and signaling pathways used by immune complexes in other human diseases...
  6. ncbi The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin
    Tamar Aprahamian
    Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 182:340-6. 2009
    ..These experiments suggest that PPARgamma agonists may be useful agents for the treatment of SLE. They also demonstrate that induction of adiponectin is a major mechanism underlying the immunomodulatory effects of PPARgamma agonists...
  7. ncbi Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop
    Nathaniel M Green
    Department of Microbiology, Boston University School of Medicine, Boston, MA 02118, USA
    J Immunol 183:1569-76. 2009
    ..These results highlight subtle differences in the IFN dependence of TLR7 responses compared with other TLR-mediated B cell responses...
  8. ncbi Role of immunostimulatory DNA and TLR9 in gene therapy
    Kei Yasuda
    Renal Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Crit Rev Ther Drug Carrier Syst 23:89-110. 2006
    ..Moreover, recent research shows that TLR9-independent immunoactivation could take place. Here, we have attempted to present an overview of immunoactivation by DNA to optimize DNA-based therapies...